Crescent Biopharma (Nasdaq: CBIO) announced inducement option grants to two non-executive employees totaling 12,525 ordinary shares under its 2025 Employment Inducement Incentive Award Plan, as amended. Grants were approved April 23, 2026, with a 10-year term and an exercise price of $25.70.
Options vest 25% after one year then 1/48th monthly thereafter, subject to continuous service and plan terms.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – CBIO
+1.41%
6 alerts
+1.41%Session close to close
-4.2%Trough in 55 min
$679.37MMarket Cap
0.2xRel. Volume
In the Apr 27 session, CBIO gained 1.41%, reflecting a mild positive market reaction.
Argus tracked a trough of -4.2% from its starting point during tracking.
Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
This announcement details a standard inducement option grant of 12,525 shares to two non‑executive e...
Analysis
This announcement details a standard inducement option grant of 12,525 shares to two non‑executive employees, with a 10‑year term, an exercise price of $25.70, and typical one‑year cliff then monthly vesting. It continues a series of similar updates seen in February and March 2026. Investors monitoring Crescent Biopharma may focus more on upcoming clinical and financial milestones, while noting that repeated grants modestly expand potential future share issuance under the 2025 Inducement Plan.
Key Figures
Inducement option shares:12,525 sharesNumber of employees:2 employeesOption term:10 years+5 more
8 metrics
Inducement option shares12,525 sharesOptions granted to two non‑executive employees under 2025 Inducement Plan
Number of employees2 employeesRecipients of inducement option awards
Option term10 yearsDuration of granted stock options
Exercise price$25.70Closing price on Nasdaq on April 23, 2026
Initial vesting fraction1/4 of sharesVests on first anniversary of each employee’s start date
Ongoing vesting rate1/48 of shares monthlyMonthly vesting after first anniversary, contingent on continuous service
Plan year2025Crescent Biopharma Employment Inducement Incentive Award Plan
Price change before news-4.74%CBIO 24‑hour move prior to this announcement
Inducement options totaling 24,600 shares to two employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Inducement award press releases have previously coincided with both strong gains and mild moves, indicating inconsistent price responses to this recurring HR-related news type.
Recent Company History
Over the past several months, Crescent Biopharma has repeatedly issued inducement award announcements on Feb 17, Mar 5, and Mar 26, 2026, each detailing option grants with 10‑year terms and standard one‑year cliff then monthly vesting. Price reactions to those awards ranged from modest moves to a 20.78% gain. Alongside these, the company reported Q4 and full‑year 2025 results and business highlights on Feb 26, 2026, and outlined investor conference participation, framing today’s grants within an active corporate update cadence.
"options to purchase an aggregate of 12,525 shares ... as equity inducement awards under"
Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.
nasdaq listing rule 5635(c)(4)regulatory
"material to each employee's acceptance of employment ... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"a 10-year term and an exercise price equal to $25.70, the closing price per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
WALTHAM, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 12,525 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on April 23, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options were granted with a 10-year term and an exercise price equal to $25.70, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on April 23, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
How many shares did Crescent Biopharma (CBIO) grant as inducement awards on April 23, 2026?
Crescent granted options to purchase an aggregate of 12,525 shares to two non-executive employees. According to the company, the grants were approved on April 23, 2026 and issued under the 2025 Employment Inducement Incentive Award Plan.
What exercise price and term apply to the CBIO inducement options granted April 23, 2026?
The options carry a $25.70 exercise price and a 10-year term. According to the company, $25.70 was the Nasdaq closing price on April 23, 2026 and sets the per‑share exercise price for the grants.
What is the vesting schedule for the Crescent Biopharma (CBIO) inducement option awards?
Options vest with 25% after one year and then 1/48th monthly thereafter. According to the company, vesting is subject to continuous service through each vesting date and the terms of the applicable option agreements.
Were the CBIO inducement awards tied to Nasdaq listing rules or employee hiring?
Yes. The grants were approved as inducement awards and were described as material to each employee’s acceptance of employment. According to the company, this conforms with Nasdaq Listing Rule 5635(c)(4) requirements for inducement grants.
Under which plan were Crescent Biopharma (CBIO) inducement options granted?
The options were granted under the 2025 Employment Inducement Incentive Award Plan, as amended. According to the company, each option is also subject to the specific terms and conditions of an individual option agreement covering the grant.
Who received the inducement option grants from Crescent Biopharma (CBIO)?
The grants were made to two non-executive employees as equity inducement awards. According to the company, the grants were material to each employee’s acceptance of employment with Crescent and were approved by the independent Compensation Committee.
